Migraine market

Aug 12, 2025

Teva’s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma’s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression/Bipolar Depression; Boehringer Ingelheim’s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab’s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed/Refractory Follicular Lymphoma; Tiziana’s Phase II IND Cleared by FDA for Multiple System Atrophy

Nov 29, 2021

Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics

Jun 09, 2021

Migraine Market: How Pharma Companies are trying to Uncomplicate the Disease and Bring in Novel Therapies

Newsletter/Whitepaper